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Private practice: Adapt or die
To the Editor: All doctors in private practice should be well 
aware that the National Health Insurance (NHI) scheme is 
a clear and inevitable danger. To judge from the comments 
of ANC luminaries, the government will probably do its 
usual bull-in-a-china-shop act by ramming the bill through 
parliament without much regard for the opinions of other 
stakeholders. And if the government’s past form in handling 
health care is anything to go by, implementation of NHI in 
South Africa is likely to be a disaster.
With this sword hanging over our collective heads, the lack 
of any real debate or innovative thinking among doctors in 
private practice is quite astounding. The prohibitive cost of the 
system has indeed been pointed out, that many or most young 
doctors will emigrate, and that health care delivery via the NHI 
will be sadly ineffective – as is generally the case with state-run 
systems. But, so far, the ANC has given every indication that 
these arguments will have little influence on their decision.
Is there anything that we (and by ‘we’, I mean all doctors in 
private practice) can do to avert the coming disaster?
I believe that an important first step is to realise that 
unbridled medical consumerism, as is practised in South 
Africa today, is something that should be of the past. Globally, 
societies are moving away from it; even in the USA, the very 
heartland of capitalism, the Obama administration is trying to 
improve the wasteful and ineffective health care system, where 
a sizeable minority have no medical care at all. In South Africa, 
with its preponderance of indigent people, the status quo is all 
the more unsustainable. Let us therefore accept that changes 
are inevitable.
For private practice to survive, compromises will have to be 
made, and perhaps some profound ones at that. As an example 
of what I mean, consider the following suggestion: that we 
volunteer to help in state hospitals for a certain time period 
each week. It would hardly be deleterious for a practitioner 
to spend, say, 3 hours a week caring for indigent patients, and 
it could send out a powerful and positive message. Imagine 
what a difference it would make if private practitioners 
assisted widespread in public facilities, working with their 
characteristic efficiency! (It may also help us to rediscover our 
roots as doctors – the establishment of a mini-Médecins Sans 
Frontières …)
In addition, a gesture like this could just make the 
implementation of NHI superfluous or, at the very least, 
give us more bargaining power. I must stress, however, that 
(i) to achieve any meaningful results, such a scheme would 
have to be implemented on a large scale, with every private 
practitioner getting involved (granted, it might not be all that 
voluntary); and (ii) we will have to think of further ways to 
tackle the problem.
Obviously, all the other stakeholders in the health 
care industry will have to contribute. Private hospitals, 
pharmaceutical companies and well-off medical aid companies 
will, in the interests of their own survival, have to make some 
compromises.
All is not lost. But we need to initiate some action right now.
Willem Theron
Eugene Marais Hospital
Pretoria
theronpw@mweb.co.za
A fairer deal for pneumococcal  
vaccination
To the Editor: In South Africa, 51 300 children under 5 die each 
year; pneumonia is a leading cause.1 The incidence of invasive 
pneumococcal disease has more than doubled in the last two 
decades, to >500 per 100 000 children. This rise is associated 
with the HIV epidemic, with 75% of cases of invasive 
pneumococcal disease occurring in HIV-infected children.2
The launch of PCV-7 as part of the primary immunisation 
programme in September 2008 was welcome news. However, 
recent negotiations by other developing countries have shown 
that South Africa is paying far more than it should for a sub-
optimal vaccine formulation.
In September 2009, the Brazilian Government negotiated 
a deal to obtain GSK’s 10-valent vaccine for $US17 per dose, 
falling to $US7 in time.3 Despite Brazil having an almost 
identical GDP to that of South Africa,4 the South African 
government is paying $26 per dose for Wyeth’s 7-valent 
vaccine (in the private sector, the cost is as high as $US60 
per dose). While PCV-7 covers 70% of invasive isolates and 
is therefore a worthwhile vaccine to roll out, PCV-10 would 
increase coverage to up to 85%.5
The usual justification given by manufacturers for the 
high cost of medicines and vaccines is the need to make 
a return on their R&D investment; but Wyeth has already 
netted its manufacturer over US$2.7 billion in worldwide 
sales of PCV-7.6 Given that South Africa participated in 
the clinical development of pneumococcal vaccines,7 it 
would seem reasonable that the country be accorded a 
fairer price, particularly because the high cost is hampering 
implementation in some provinces. A more affordable vaccine 
would encourage the provision of adequate stocks across the 
country and allow vaccination plans to include a catch-up 
strategy for older children to ensure maximum coverage.
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South Africa’s Department of Health can ill afford to pay for 
costly interventions when cheaper alternatives exist. A recent 
Treasury report made it clear that the health sector needed to 
make efforts to achieve optimal value for money; insisting on a 
better price for PCV would be a good place to start.
Nathan Ford
Médecins sans Frontières
Johannesburg
nathan.ford@joburg.msf.org
Daniel Berman
Access to Essential Medicines Project
Médecins sans Frontières
Geneva
Lisa Frigati
Red Cross War Memorial Children’s Hospital
Cape Town
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A jaw for a tooth
To the Editor: I fully support the sentiments expressed by Dr 
N T Ospovat1 when he criticised the Editor for producing an 
editorial which has little to do with medicine and much to do 
with politics.2
It is not the province of the Editor of the SAMJ to embark on 
a career of political journalism in our journal. He has abused 
his position as Editor and foisted upon us his naïve and 
bigoted political views. In most Western countries, the Editor 
would be asked to resign, in consequence.
He owes the medical fraternity an apology.
Charles Isaacson
Emeritus Professor of Pathology
University of the Witwatersrand Medical School
Johannesburg
charlesi@worldonline.co.za
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